P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines

被引：0
|
作者：
Nitesh P Shirsath
Sonal M Manohar
Kalpana S Joshi
机构：
[1] Piramal Healthcare Limited,Oncology Franchise
[2] Piramal Healthcare Limited,Target Identification Group
来源：
Molecular Cancer | / 11卷
关键词：
Mantle cell lymphoma; Cdk inhibitors; P276-00; Cyclin D1; Mcl-1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines
    Shirsath, Nitesh P.
    Manohar, Sonal M.
    Joshi, Kalpana S.
    MOLECULAR CANCER, 2012, 11
  • [2] In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00
    Joshi, Kalpana S.
    Rathos, Maggie J.
    Joshi, Rajendra D.
    Sivakumar, Meenakshi
    Mascarenhas, Malcolm
    Kamble, Shrikant
    Lal, Bansi
    Sharma, Somesh
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (03) : 918 - 925
  • [3] Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells
    Rathos, Maggie J.
    Khanwalkar, Harshal
    Joshi, Kavita
    Manohar, Sonal M.
    Joshi, Kalpana S.
    BMC CANCER, 2013, 13
  • [4] Induction of cell cycle arrest and apoptosis in mantle cell lymphoma by AZD5438, a novel cyclin-dependent kinase inhibitor
    Lo, Wann-Cheng
    Growcott, Jim
    LeBrun, David P.
    Greer, Peter A.
    CANCER RESEARCH, 2010, 70
  • [5] Potentiation of in vitro and in vivoantitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells
    Maggie J Rathos
    Harshal Khanwalkar
    Kavita Joshi
    Sonal M Manohar
    Kalpana S Joshi
    BMC Cancer, 13
  • [6] A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Cassaday, Ryan D.
    Goy, Andre
    Advani, Suresh
    Chawla, Purvi
    Nachankar, Rajesh
    Gandhi, Mansi
    Gopal, Ajay K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (07): : 392 - 397
  • [7] Multiple mechanisms of Mcl-1 depletion by the cyclin-dependent kinase inhibitor flavopiridol in mantle cell lymphoma cell lines
    Shimamura, Takeshi
    Lowell, April M.
    Kobayashi, Susumu
    Tenen, Daniel G.
    Shapiro, Geoffrey I.
    CANCER RESEARCH, 2006, 66 (08)
  • [8] Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines
    Shirsath, Nitesh
    Rathos, Maggie
    Chaudhari, Umesh
    Sivaramakrishnan, H.
    Joshi, Kalpana
    LUNG CANCER, 2013, 82 (02) : 214 - 221
  • [9] Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers
    Rathos, Maggie J.
    Joshi, Kavita
    Khanwalkar, Harshal
    Manohar, Sonal M.
    Joshi, Kalpana S.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [10] Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
    N Raje
    T Hideshima
    S Mukherjee
    M Raab
    S Vallet
    S Chhetri
    D Cirstea
    S Pozzi
    C Mitsiades
    M Rooney
    T Kiziltepe
    K Podar
    Y Okawa
    H Ikeda
    R Carrasco
    P G Richardson
    D Chauhan
    N C Munshi
    S Sharma
    H Parikh
    B Chabner
    D Scadden
    K C Anderson
    Leukemia, 2009, 23 : 961 - 970
12345